Skip to main content
Premium Trial:

Request an Annual Quote

People in the News at Mainz Biomed, Stilla Technologies, Singular Genomics, Berkeley Lights, More

Mainz Biomed: Frank Krieg-Schneider

Mainz Biomed has appointed Frank Krieg-Schneider as VP of development. He will lead commercialization efforts across the company's portfolio of cancer detection products including its flagship ColoAlert test. Krieg-Schneider most recently led the clinical diagnostics division at Germany's R-Biopharm. He also previously served as CEO of molecular diagnostics firm GNA Biosolutions, and prior to that spent two decades in senior management and executive roles with Qiagen, including head of R&D for diagnostic sample preparation and head of global strategic alliances.

Stilla Technologies: Yvan Sergeant

Stilla Technologies has appointed Yvan Sergeant to the position of VP and general manager of the Europe, Middle East, and Africa (EMEA) region. Sergeant held prior leadership positions at PerkinElmer, Caliper Life Sciences, and Trinean. He joins Stilla from Quanterix, where he served as VP and general manager of that firm's European business.

Singular Genomics: Sam Ropp, Jeff Bullard

Singular Genomics has appointed Sam Ropp as chief commercial officer. Reporting to CEO Drew Spaventa, he will oversee commercialization of the G4 sequencing platform. Ropp joins Singular from 10x Genomics, where he was senior VP of global sales. He has also held leadership roles at Becton Dickinson, Molecular Devices, and Bio-Rad Laboratories. He holds a doctorate in biomedical sciences from Wright State University.

Singular also appointed Jeff Bullard as head of sales for North America. Bullard also joins Singular from 10x Genomics, where he was senior director of sales for the Americas. Prior to that, he held a variety of roles at Thermo Fisher Scientific, Life Technologies, Ion Torrent, and Applied Biosystems.

Berkeley Lights: Rolando Brawer

Berkeley Lights has appointed Rolando Brawer as executive VP of strategy and corporate development. Brawer previously served as VP of science and technology, alliances and ventures at Danaher and as VP of corporate development at Exact Sciences. He also led Thermo Fisher Scientific's global strategy for out-licensing and commercial supply for the company's Life Science Solutions Group. Brawer started his corporate development career at Invitrogen/Life Technologies.

For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.